WallStSmart

Medtronic PLC (MDT)vsNovocure Ltd (NVCR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Medtronic PLC generates 5269% more annual revenue ($37.54B vs $699.19M). MDT leads profitability with a 13.9% profit margin vs -21.2%. MDT earns a higher WallStSmart Score of 68/100 (B-).

MDT

Strong Buy

68

out of 100

Grade: B-

Growth: 7.3Profit: 6.5Value: 5.3Quality: 6.5
Piotroski: 5/9Altman Z: 1.99

NVCR

Avoid

29

out of 100

Grade: F

Growth: 5.3Profit: 2.0Value: 6.7Quality: 5.0
Piotroski: 3/9Altman Z: -0.92
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

MDTUndervalued (+3.7%)

Margin of Safety

+3.7%

Fair Value

$94.43

Current Price

$90.96

$3.47 discount

UndervaluedFair: $94.43Overvalued
NVCRUndervalued (+81.5%)

Margin of Safety

+81.5%

Fair Value

$56.59

Current Price

$15.51

$41.08 discount

UndervaluedFair: $56.59Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

MDT4 strengths · Avg: 8.3/10
Market CapQuality
$116.35B9/10

Large-cap with strong market position

Price/BookValuation
2.3x8/10

Reasonable price relative to book value

EPS GrowthGrowth
40.7%8/10

Earnings expanding 40.7% YoY

Free Cash FlowQuality
$1.29B8/10

Generating 1.3B in free cash flow

NVCR1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
15.6%8/10

15.6% revenue growth

Areas to Watch

MDT2 concerns · Avg: 4.0/10
PEG RatioValuation
1.654/10

Expensive relative to growth rate

Altman Z-ScoreHealth
1.994/10

Grey zone — moderate risk

NVCR4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-52.3%2/10

ROE of -52.3% — below average capital efficiency

EPS GrowthGrowth
-6.0%2/10

Earnings declined 6.0%

Altman Z-ScoreHealth
-0.922/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : MDT

The strongest argument for MDT centers on Market Cap, Price/Book, EPS Growth. Revenue growth of 13.7% demonstrates continued momentum.

Bull Case : NVCR

The strongest argument for NVCR centers on Revenue Growth. Revenue growth of 15.6% demonstrates continued momentum.

Bear Case : MDT

The primary concerns for MDT are PEG Ratio, Altman Z-Score.

Bear Case : NVCR

The primary concerns for NVCR are Piotroski F-Score, Return on Equity, EPS Growth.

Key Dynamics to Monitor

MDT profiles as a value stock while NVCR is a growth play — different risk/reward profiles.

NVCR carries more volatility with a beta of 1.01 — expect wider price swings.

NVCR is growing revenue faster at 15.6% — sustainability is the question.

MDT generates stronger free cash flow (1.3B), providing more financial flexibility.

Bottom Line

MDT scores higher overall (68/100 vs 29/100) and 13.7% revenue growth. NVCR offers better value entry with a 81.5% margin of safety. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Medtronic PLC

HEALTHCARE · MEDICAL DEVICES · USA

Medtronic plc is an American-Irish registered medical device company that primarily operates in the United States. Medtronic has an operational and executive headquarters in Fridley, Minnesota in the US.

Novocure Ltd

HEALTHCARE · MEDICAL DEVICES · USA

NovoCure Limited, an oncology company, is engaged in the development, manufacture and marketing of Optune for the treatment of a variety of solid tumors. The company is headquartered in Saint Helier, Jersey.

Want to dig deeper into these stocks?